Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
NURO's Cash to Debt is ranked higher than
97% of the 317 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.05 vs. NURO: No Debt )
NURO' s 10-Year Cash to Debt Range
Min: 0.63   Max: No Debt
Current: No Debt

Equity to Asset 0.18
NURO's Equity to Asset is ranked lower than
51% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. NURO: 0.18 )
NURO' s 10-Year Equity to Asset Range
Min: -6.3   Max: 0.91
Current: 0.18

-6.3
0.91
Interest Coverage No Debt
NURO's Interest Coverage is ranked higher than
87% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 38.48 vs. NURO: No Debt )
NURO' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 1
Z-Score: -24.99
M-Score: 73.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -188.25
NURO's Operating margin (%) is ranked lower than
53% of the 314 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.05 vs. NURO: -188.25 )
NURO' s 10-Year Operating margin (%) Range
Min: -261.35   Max: 5.18
Current: -188.25

-261.35
5.18
Net-margin (%) -157.60
NURO's Net-margin (%) is ranked lower than
53% of the 314 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.89 vs. NURO: -157.60 )
NURO' s 10-Year Net-margin (%) Range
Min: -251.65   Max: 7.72
Current: -157.6

-251.65
7.72
ROE (%) -172.76
NURO's ROE (%) is ranked lower than
55% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.20 vs. NURO: -172.76 )
NURO' s 10-Year ROE (%) Range
Min: -146.78   Max: 10.91
Current: -172.76

-146.78
10.91
ROA (%) -73.09
NURO's ROA (%) is ranked lower than
55% of the 318 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. NURO: -73.09 )
NURO' s 10-Year ROA (%) Range
Min: -135.91   Max: 8.66
Current: -73.09

-135.91
8.66
ROC (Joel Greenblatt) (%) -3602.24
NURO's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.46 vs. NURO: -3602.24 )
NURO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3242.14   Max: 124.95
Current: -3602.24

-3242.14
124.95
Revenue Growth (3Y)(%) -63.50
NURO's Revenue Growth (3Y)(%) is ranked lower than
54% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.60 vs. NURO: -63.50 )
NURO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -63.5   Max: 4.3
Current: -63.5

-63.5
4.3
EBITDA Growth (3Y)(%) -56.40
NURO's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 234 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. NURO: -56.40 )
NURO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -59.4   Max: 8.8
Current: -56.4

-59.4
8.8
EPS Growth (3Y)(%) -58.50
NURO's EPS Growth (3Y)(%) is ranked higher than
50% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. NURO: -58.50 )
NURO' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.5   Max: 3.4
Current: -58.5

-58.5
3.4
» NURO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NURO Guru Trades in Q3 2013

Jim Simons 87,925 sh (-3.72%)
» More
Q4 2013

NURO Guru Trades in Q4 2013

Jim Simons 78,950 sh (-10.21%)
» More
Q1 2014

NURO Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q1 2015

NURO Guru Trades in Q1 2015

Jim Simons 20,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NURO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.10
NURO's P/B is ranked lower than
54% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. NURO: 6.10 )
NURO' s 10-Year P/B Range
Min: 0.27   Max: 13.18
Current: 6.1

0.27
13.18
P/S 1.60
NURO's P/S is ranked higher than
79% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.10 vs. NURO: 1.60 )
NURO' s 10-Year P/S Range
Min: 0.2   Max: 15.14
Current: 1.6

0.2
15.14
EV-to-EBIT -0.39
NURO's EV-to-EBIT is ranked higher than
55% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.63 vs. NURO: -0.39 )
NURO' s 10-Year EV-to-EBIT Range
Min: -2675.3   Max: 408.7
Current: -0.39

-2675.3
408.7
Current Ratio 2.48
NURO's Current Ratio is ranked higher than
70% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. NURO: 2.48 )
NURO' s 10-Year Current Ratio Range
Min: 2.29   Max: 13.01
Current: 2.48

2.29
13.01
Quick Ratio 2.29
NURO's Quick Ratio is ranked higher than
80% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. NURO: 2.29 )
NURO' s 10-Year Quick Ratio Range
Min: 1.79   Max: 12.52
Current: 2.29

1.79
12.52
Days Inventory 90.62
NURO's Days Inventory is ranked higher than
86% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 136.69 vs. NURO: 90.62 )
NURO' s 10-Year Days Inventory Range
Min: 81.73   Max: 246.22
Current: 90.62

81.73
246.22
Days Sales Outstanding 61.58
NURO's Days Sales Outstanding is ranked higher than
78% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 70.75 vs. NURO: 61.58 )
NURO' s 10-Year Days Sales Outstanding Range
Min: 27.03   Max: 73.73
Current: 61.58

27.03
73.73

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.00
NURO's Price/Tangible Book is ranked higher than
73% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.10 vs. NURO: 6.00 )
NURO' s 10-Year Price/Tangible Book Range
Min: 0.44   Max: 13.02
Current: 6

0.44
13.02
Price/Median PS Value 1.40
NURO's Price/Median PS Value is ranked higher than
77% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.34 vs. NURO: 1.40 )
NURO' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 10.68
Current: 1.4

0.29
10.68
Earnings Yield (Greenblatt) -271.40
NURO's Earnings Yield (Greenblatt) is ranked lower than
66% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.60 vs. NURO: -271.40 )
NURO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -269.1   Max: 3374.7
Current: -271.4

-269.1
3374.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:NLZB.Germany,
NeuroMetrix Inc was incorporated in Delaware in June 1996. The Company is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company develops and markets neurodiagnostic systems which consist of a medical device plus single patient-use biosensors or electrodes. Other accessories are also offered to its customers. The Company's product portfolio includes NC-stat DPN check for Diabetes Diagnostics; Sensus for Pain Management and Advance NCS/EMG System for Orthopedics & Neurology. NC-stat DPNCheck is a fast, accurate, and quantitative nerve conduction test that is used to evaluate systemic neuropathies such as DPN. It is designed to be used by primary care physicians, endocrinologists, podiatrists and other clinicians at the point-of-care to objectively detect, stage, and monitor DPN. The device measures nerve conduction velocity and response amplitude of the sural nerve, a nerve in the lower leg and ankle. These parameters are recognized as sensitive and specific biomarkers of DPN. The Company also markets a medical device, which has been cleared by the FDA and which is used for the assessment of neuropathies such as carpal tunnel syndrome, diabetes, and sciatica. Its ADVANCE NCS/EMG System, or the ADVANCE System, which is a part of its legacy neurodiagnostics business, is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures. Its ADVANCE System is comprised of; various types of electrodes and needles, its ADVANCE device and related modules, and a communication hub that enables the physician's office to network their device to its servers for data archiving, report generation and other network services. The Company competes with CareFusion Corporation, Cadwell Laboratories, Inc., and Natus Medical Incorporated. The Company's products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the regulations promulgated thereunder, as well as by other regulatory bodies in the United States and abroad.
» More Articles for NURO

Headlines

Articles On GuruFocus.com
NeuroMetrix Inc. (NURO) CEO Shai Gozani buys 200,000 Shares Nov 18 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) Nov 09 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) Aug 10 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) May 14 2010 
NeuroMetrix, Inc. Announces Second Quarter 2009 Financial Results Aug 05 2009 
NeuroMetrix Inc. (NURO) CEO Shai Gozani buys 100,000 Shares Mar 03 2009 
NeuroMetrix, Inc. Reports Total Revenues of $7.2 Million for the Fourth Quarter of 2008 Feb 10 2009 
Nucor Invites You to Join Its Fourth Quarter and Year End of 2008 Conference Call on the Web Jan 02 2009 
Nucor Announces One-Hundred Forty-Third (143rd) Consecutive Cash Dividend Dec 09 2008 

More From Other Websites
NeuroMetrix Announces First Shipments of Quell™ Wearable Pain Relief Device May 13 2015
NeuroMetrix Announces First Shipments of Quell™ Wearable Pain Relief Device May 13 2015
NeuroMetrix To Start Shipping Quell™ Wearable Pain Relief Device In June May 07 2015
NeuroMetrix Continues Progress to Launch of Quell Wearable Pain Relief with Availability of iOS App Apr 28 2015
NeuroMetrix Continues Progress to Launch of Quell Wearable Pain Relief with Availability of iOS App Apr 28 2015
10-Q for NeuroMetrix, Inc. Apr 26 2015
NeuroMetrix Inc Earnings Call scheduled for 8:00 am ET today Apr 21 2015
NeuroMetrix Reports Q1 2015 Financial Results and Highlights Apr 21 2015
HTML PDF Apr 21 2015
Q1 2015 NeuroMetrix Inc Earnings Release - Before Market Open Apr 21 2015
NeuroMetrix Reports Q1 2015 Financial Results and Highlights Apr 21 2015
HTML PDF Apr 19 2015
NeuroMetrix, Inc. Announces Date for 2015 First Quarter Financial Results Conference Call Apr 17 2015
NeuroMetrix, Inc. Announces Date for 2015 First Quarter Financial Results Conference Call Apr 17 2015
NeuroMetrix Exceeds Indiegogo Campaign Goal for Quell™ Wearable Pain Relief Technology in 48 hours Mar 04 2015
NeuroMetrix Exceeds Indiegogo Campaign Goal for Quell™ Wearable Pain Relief Technology in 48 hours Mar 04 2015
HTML PDF Mar 02 2015
NeuroMetrix Launches Indiegogo Campaign for Quell™ Wearable Pain Relief Technology Mar 02 2015
NeuroMetrix Launches Indiegogo Campaign for Quell™ Wearable Pain Relief Technology Mar 02 2015
10-K for NeuroMetrix, Inc. Feb 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK